GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | CEBPA | increases expression | EXP | | 6480464 | CTD | Dexamethasone results in increased expression of CEBPA mRNA | PMID:24418828 PMID:27003841 | CEBPA | multiple interactions | EXP | | 6480464 | CTD | [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA mRNA; [Bismuth affects the susceptibility to [INS protein co-treated with Dexamethasone co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine]] which results in decreased expression of CEBPA mRNA; [bisphenol F co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA; [bisphenol F co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein; [bisphenol S co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CEBPA protein; [bisphenol S co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA; [Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Vitamin D co-treated with bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] affects the expression of CEBPA mRNA; cordycepin inhibits the reaction [[Dexamethasone co-treated with Insulin co-treated with Indomethacin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; sodium arsenite inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA] | PMID:23152186 PMID:25932594 PMID:28628672 PMID:33476690 PMID:33836827 PMID:33865937 PMID:34560244 PMID:34575692 | CEBPA | increases expression | ISO | Cebpa (Mus musculus) | 6480464 | CTD | Dexamethasone results in increased expression of CEBPA mRNA | PMID:22956630 PMID:25068083 | CEBPA | increases expression | ISO | Cebpa (Rattus norvegicus) | 6480464 | CTD | Dexamethasone results in increased expression of CEBPA mRNA; Dexamethasone results in increased expression of CEBPA protein | PMID:12837037 PMID:15965953 PMID:32494933 | CEBPA | multiple interactions | ISO | Cebpa (Mus musculus) | 6480464 | CTD | (+)-JQ1 compound inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Troglitazone] results in increased expression of CEBPA protein]; (+)-JQ1 compound inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; (+)-JQ1 compound inhibits the reaction [Rosiglitazone promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with perfluorooctanoic acid] results in increased expression of CEBPA mRNA]; 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; 3,5,6-trichloro-2-pyridinol promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA]; 3,5,6-trichloro-2-pyridinol promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA protein]; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA protein; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] affects the expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA protein; [bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA mRNA; [bisphenol S co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] affects the expression of CEBPA protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA; [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA protein; [Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with perfluorooctanoic acid] results in increased expression of CEBPA mRNA; [Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA mRNA; [Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA; [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA protein; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Troglitazone] results in increased expression of CEBPA protein; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA; [INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA protein; [INS1 protein co-treated with Dexamethasone] results in increased expression of CEBPA mRNA; [Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CEBPA mRNA; [sodium arsenite co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CEBPA mRNA; [Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA]; Acrylamide promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA mRNA]; Acrylamide promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA protein]; andrographolide affects the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] affects the expression of CEBPA mRNA]; andrographolide inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA protein]; APCDD1 protein promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; butylparaben promotes the reaction [Dexamethasone results in increased expression of CEBPA mRNA]; cannabidiolic acid promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; Chlorpyrifos promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA]; Chlorpyrifos promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; Curcumin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]]; Glycyrrhizic Acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA]; hispidulin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Ivermectin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA protein]; IWR-1 compound inhibits the reaction [Raloxifene Hydrochloride inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA protein]]; JMJD6 mutant form inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Troglitazone] results in increased expression of CEBPA protein]; Palmitic Acid promotes the reaction [[sodium arsenite co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CEBPA mRNA]; pentagalloylglucose inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA mRNA]; pentagalloylglucose inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA protein]; Quercetin inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA protein]; Raloxifene Hydrochloride inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]; Ritonavir inhibits the reaction [[INS1 protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone] results in increased expression of CEBPA protein]; Rosiglitazone promotes the reaction [[Dexamethasone co-treated with INS1 protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; Rosiglitazone promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; Rosiglitazone promotes the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; rotenoisin A inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; rotenoisin A inhibits the reaction [[INS1 protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA protein]; Silybin inhibits the reaction [[1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in increased expression of CEBPA protein]; sodium arsenite inhibits the reaction [[INS1 protein co-treated with Dexamethasone] results in increased expression of CEBPA mRNA]; sodium arsenite promotes the reaction [[Palmitic Acid co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS1 protein] results in decreased expression of CEBPA mRNA]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; sodium pentaborate inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CEBPA mRNA] | PMID:11101056 PMID:11812925 PMID:16054899 PMID:18586010 PMID:22298784 PMID:22956630 PMID:23503329 PMID:25559859 PMID:26117538 PMID:26972250 PMID:27475717 PMID:28242765 PMID:28285642 PMID:28595985 PMID:29094436 PMID:30055130 PMID:30409764 PMID:30446312 PMID:30611848 PMID:30665118 PMID:30721698 PMID:31009676 PMID:31199990 PMID:31470850 PMID:32017950 PMID:32220626 PMID:33412187 PMID:34302803 PMID:34968464 PMID:9543393 | CEBPA | multiple interactions | ISO | Cebpa (Rattus norvegicus) | 6480464 | CTD | [Lithium Chloride co-treated with Pilocarpine] affects the reaction [Dexamethasone results in increased expression of CEBPA mRNA] | PMID:32494933 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |